All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This product is the plasmid containing an encoded anti-KRT18 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.
Sub CAT. | DMAb Clone | DMAb Host | Target Species | DMAb Isotype | DMAb Immunogen | |
DMAb-1472-CQ | Ks18.04 | Mouse | IgG1 | Cytoskeleton preparation of epidermal carcinoma cell line A431 | ||
DMAb-1473-CQ | DA7 | Mouse | Human | IgG1, κ | Human breast cancer PMC 42 cells | |
DMAb-1474-CQ | DC10 | Mouse | Human | IgG1 | Human breast cancer PMC 42 cells | |
DMAb-1475-CQ | DE-K18 | Mouse | IgG1, κ | Cytoskeletal preparation extracted from the human vulvar squamous carcinoma cell line A431 | ||
DMAb-1476-CQ | KRT18/1190 | Mouse | IgG1, κ | Recombinant human KRT18 protein | ||
DMAb-1477-CQ | KRT18/834 | Mouse | Human | IgG1 | Recombinant Full length human KRT18 protein | |
DMAb-1478-CQ | KRT18/836 | Mouse | IgG1 | Recombinant human KRT18 protein | ||
DMAb-1479-CQ | LC18N | Mouse | Human | IgG1 | Synthetic pepide of N terminus of human keratin 18 (NH2-SFTTRSTFSC) | |
DMAb-1480-CQ | LDK18 | Mouse | IgG1 | Synthetic peptide of human keratin 18 (CSETNDTKVLRH-COOH) | ||
DMAb-1481-CQ | RCK106 | Mouse | Human | IgG1 | Cytokeratins from the human bladder carcinoma cell line T24 | |
DMAb-1482-CQ | RGE53 | Mouse | IgG1 | A cytoskeletal preparation of cells | ||
DMAb-1483-CQ | SPM265 | Mouse | Human | IgG1 | PMC-42 human breast carcinoma cells | |
DMAb-1484-CQ | SPM510 | Mouse | Human | IgG1, κ | Human breast cancer PMC 42 cells | |
DMAb-1486-CQ | M6 | Mouse | Human | IgG2a | Keratin 18 (K18) fragments purified from human carcinomas | |
DMAb-1487-CQ | M30 | Mouse | Human | IgG2b | Keratin 18 (K18) fragments purified from supernatant from human carcinoma cell line WiDr CCL218 | |
DMAb-1490-CQ | B23.1 | Mouse | Human | IgG1 | PMC-42 human breast carcinoma cells | |
DMAb-1491-CQ | RM279 | Rabbit | Human | IgG | A peptide corresponding to the N-terminus of human Cytokeratin 18 | |
DMAb-0886-WJ | C-04 | Mouse | IgG1 | Cytoskeleton preparation of epidermal carcinoma cell line A431 | ||
DMAb-1473-CQ | DA7 | Mouse | Human | IgG1, κ | Human breast cancer PMC 42 cells were used as immunogen to generate the Cytokeratin 18 (CK18) antibody | |
DMAb-1474-CQ | DC10 | Mouse | Human | IgG1 | Human breast cancer PMC 42 cells were used as immunogen to generate the Keratin 18 antibody | |
DMAb-0896-WJ | Ks 18.04 | Mouse | IgG1 | Human cytokeratin 18 | ||
DMAb-1480-CQ | LDK18 | Mouse | Human | IgG1, κ | ||
DMAb-0903-WJ | CK-18 | Mouse | IgG1 | The human epidermal carcinoma A-431 and MCF-7 human breast cancer cell lines | ||
DMAb-0905-WJ | CY90 | Mouse | Human | IgG1 | Tissue / cell preparation (human epidermal carcinoma and MCF-7 human breast cancer allcells) | |
DMAb-0907-WJ | DEK-18 | Mouse | IgG1 | |||
DMAb-1478-CQ | KRT18/836 | Mouse | IgG1 | Recombinant human KRT18 protein | ||
DMAb-0916-WJ | M9 | Mouse | IgG1 |
There are currently no customer reviews or questions for Anti-KRT18 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1471-CQ). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION